UBS/CALL/BB BIOTECH N/50.003/0.0333/20.12.24

UBS/CALL/BB BIOTECH N/50.003/0.0333/20.12.24 Share Price

Warrant

NBIO4U

CH1276034886

Market Closed - Swiss Exchange 08:45:00 05/06/2024 pm IST
0.02 ^CHF	0.00%

6 months	-33.33%
Current year	-50.00%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart BB BIOTECH AG

Chart UBS/CALL/BB BIOTECH N/50.003/0.0333/20.12.24

Latest news about BB BIOTECH AG

Edison issues review on BB Biotech (BION): A recovering sector with a healthy prognosis	20/05	EQ
BB BIOTECH AG: Disclosure of Shareholdings	10/05	EQ
DD: BB BIOTECH AG: Dr. Thomas von Planta, buy	02/05	EQ
Tranche Update on BB Biotech AG?s Equity Buyback Plan announced on April 12, 2022.	27/04	CI

More news

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	BB BIOTECH AG
Issuer	UBS
	NBIO4U
ISIN	CH1276034886
Date issued	19/06/2023
Strike	50 CHF
Maturity	20/12/2024 (188 Days)
Parity	30 : 1
Emission price	0.09 CHF
Emission volume	N/A
Settlement	physical
Currency	CHF

Technical Indicators

Highest since issue	0.12 CHF
Lowest since issue	0.02 CHF
Spread	0.01 CHF
Spread %	50.00%

Company Profile

BB Biotech AG is a Switzerland-based investment company, which principal activity is to invest in companies active in the biotechnology industry. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Companyâs portfolio comprises between 20 and 35 companies and includes such companies as Celgene, Actelion, Vertex Pharmaceuticals, Gilead, Novo Nordisk, Incyte, Isis Pharmaceuticals, Immunogen, Halozyme Therapeutics, Ariad Pharmaceuticals, Biomarin Pharmaceutical, Alexion Pharmaceuticals, Optimer Pharmaceuticals, Achillion Pharmaceuticals, Swedish Orphan Biovitrum, Dendreon, Bavarian Nordic, Lupin, Glenmark Pharmaceuticals, Strides Arcolab, Endocyte, Probiodrug, and Idenix Pharmaceuticals.

Sector

More about the company